In this review and meta-analysis we evaluated the benefits of immune checkpoint inhibitors, especially the PD-1/PD-L1 inhibitors nivolumab, pembrolizumab and atezolizumab, as a second-line therapy in the management of advanced or metastatic NSCLC in real-world clinical practice. Here, CD274 is linked to non-small cell lung carcinoma.